Empower Clinics (CSE: CBDT) this morning announced that it has received a notable purchase order for its Kai Medical Laboratory subsidiary. The purchase order, anticipated to be in excess of $750,000, is for COVID-19 RT-PCR tests.
The order, which amounts to 5,000 test kits, reportedly comes from two new film and television productions. The order reportedly follows orders of 1,000 units in October, and 9,000 units in November. The order, which the company has managed to classify as both “new” and a “repeat,” is expected to see over $750,000 in total revenues over a two month period.
The company also identified this morning that the subsidiary continues to progress on the design and build out of its expansion of the Kai laboratory facility, which is expected to triple the size of the current facility. The expansion is being pursued in anticipation of rapid test growth.
Empower Clinics last traded at $0.60 on the CSE.
Information for this briefing was found via Sedar, and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.